Quick answer
The physiological feeling of fullness that ends eating and suppresses further intake between meals. GLP-1 medications enhance satiety by acting on hypothalamic and brainstem appetite centers.
Full definition
Satiety is the post-meal state of feeling full, which suppresses hunger and reduces food intake until the next eating occasion. It is regulated by gut hormones (GLP-1, PYY, CCK, leptin), gastric distension signals via the vagus nerve, and central nervous system processing in the hypothalamus and brainstem. GLP-1 receptor agonists enhance satiety through both peripheral (slowed gastric emptying) and central (direct receptor binding in arcuate nucleus) mechanisms.
Deep dive
Satiety: complete reference
Satiety is the state of being satisfied or fullness after eating, distinct from satiation (the feeling that ends a meal). Satiety determines how long until the next meal — longer satiety means longer time between eating events. Satiety is regulated by a complex network of gut hormones (GLP-1, peptide YY, CCK, leptin), neural signaling (vagal afferents), and central nervous system processing (hypothalamic + brainstem appetite centers). GLP-1 receptor agonists enhance satiety through multiple mechanisms: delayed gastric emptying (food stays in stomach longer), direct CNS appetite suppression, and modulation of food reward signaling. Patients commonly describe enhanced satiety as "feeling full longer" or "not thinking about food between meals" — distinct from "not being hungry," though related. Satiety dysfunction is a core feature of obesity; restoring satiety signals is the primary therapeutic mechanism for GLP-1 weight management.
- In practice
- Before Wegovy, you might think about lunch 2 hours after breakfast. On Wegovy, that interval often extends to 4-5 hours — you simply don't need food as soon.
- Clinical context
- Enhanced satiety is the foundation of GLP-1 weight loss — patients eat less because they don't want more, not because they're restraining hunger.
Medications
Satiety is most directly relevant to the following GLP-1 medications:
Related terms
- Food Noise — A patient-coined term for the constant, intrusive thoughts about food that GLP-1 medications often q…
- Gastric Emptying — The process by which food leaves the stomach into the small intestine. GLP-1 medications slow gastri…
- GLP-1 (Glucagon-Like Peptide-1) — GLP-1 is a natural gut hormone (incretin) released after eating that triggers insulin release, slows…
Continue learning
GLP1Zoom glossary is educational reference. Definitions are summary interpretations of clinical sources and not a substitute for prescribing-information detail. Full disclaimer.
References
Glucagon-Like Peptide-1 Receptor Agonists: Mechanisms и Clinical Use (Drucker, Cell Metabolism)(2018)
Tirzepatide GIP/GLP-1 Dual Agonism: Mechanism Review (Lancet Diabetes & Endocrinology)(2021)
GLP-1 Effects on Gastric Emptying: Pharmacology Review (American J Physiology)(2020)
Endocrine Society Clinical Practice Guideline: Pharmacological Management of Obesity(2015)
STEP-1 trial: Once-Weekly Semaglutide in Adults with Overweight or Obesity (Wilding et al., NEJM)(2021)
SURMOUNT-1 trial: Tirzepatide Once Weekly для Treatment of Obesity (Jastreboff et al., NEJM)(2022)
SUSTAIN-6 trial: Semaglutide and Cardiovascular Outcomes (Marso et al., NEJM)(2016)
SURPASS-2 trial: Tirzepatide vs Semaglutide в Type 2 Diabetes (Frias et al., NEJM)(2021)
LEADER trial: Liraglutide and Cardiovascular Outcomes в T2D (Marso et al., NEJM)(2016)